Terns Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon, everyone, and welcome to the last day of our 24th Annual Global Investment Conference. My name is George King, Equity Research Associate at H.C. Wainwright, and it's my pleasure to introduce our next speaker from Terns Pharmaceuticals. Please welcome, President and Head of R&D, Erin Quirk.
George, thanks very much for the introduction, and thanks also to you and the entire H.C. Wainwright team for the opportunity to be here today and provide an overview of Terns. And good afternoon, everyone. I invite you all to go to our website to review our forward-looking statements.
I'll spend just a moment on what I think is one of Terns' great strengths and that is our people. We have a highly seasoned management team that collectively has [scores] of years of experience in management and financing of biotechs, as well as in development of high-impact drugs. We have a stellar Board, and we are backed by a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |